Aptus Pharma shares gain on growth plan, preferential issue; key details
Aptus Pharma plans to use Rs 25 crore of the proceeds towards capital expenditure, including land acquisition, manufacturing plant structure, hi-tech storage facilities and vehicles.
- Aug 24, 2026,
- Updated Aug 24, 2026 3:26 PM IST
Aptus Pharma Ltd shares rose in Monday's trade after it outlined its next phase of growth with plans to raise Rs 44.88 crore through a preferential issue of equity shares to identified investors. Following the development, the Aptus Pharma stock rose 1.99 per cent to hit a high of Rs 296.40 on the BSE.
As per the company filing, Aptus Pharma plans to use Rs 25 crore of the proceeds towards capital expenditure, including land acquisition, manufacturing plant structure, hi-tech storage facilities and vehicles. Another Rs 10 crore will be used for working capital, while Rs 9.88 crore has been earmarked for general corporate purposes, including business expansion, strengthening its financial position and debt reduction.
The preferential issue is subject to approval from shareholders at the company's Annual General Meeting scheduled for September 14, 2026, as well as other applicable statutory and regulatory approvals. The proceeds are proposed to be utilised within 36 months of receiving the funds.
As part of its manufacturing strategy, Aptus Pharma aims to eventually meet around 20 per cent of its product requirements through in-house manufacturing. The company expects this to give it greater control over product quality, supply-chain management and product availability, while supporting the development of its own brand portfolio.
On the domestic front, the company plans to strengthen its sales and distribution network across West, Central, East and South India as it moves towards a broader Pan-India presence.
Aptus Pharma also plans to explore opportunities in Africa, the Middle East and Latin America through product registrations, export partnerships and other business arrangements. The company said the expansion will be pursued based on commercial viability, market conditions and regulatory approvals.
Aptus Pharma Ltd shares rose in Monday's trade after it outlined its next phase of growth with plans to raise Rs 44.88 crore through a preferential issue of equity shares to identified investors. Following the development, the Aptus Pharma stock rose 1.99 per cent to hit a high of Rs 296.40 on the BSE.
As per the company filing, Aptus Pharma plans to use Rs 25 crore of the proceeds towards capital expenditure, including land acquisition, manufacturing plant structure, hi-tech storage facilities and vehicles. Another Rs 10 crore will be used for working capital, while Rs 9.88 crore has been earmarked for general corporate purposes, including business expansion, strengthening its financial position and debt reduction.
The preferential issue is subject to approval from shareholders at the company's Annual General Meeting scheduled for September 14, 2026, as well as other applicable statutory and regulatory approvals. The proceeds are proposed to be utilised within 36 months of receiving the funds.
As part of its manufacturing strategy, Aptus Pharma aims to eventually meet around 20 per cent of its product requirements through in-house manufacturing. The company expects this to give it greater control over product quality, supply-chain management and product availability, while supporting the development of its own brand portfolio.
On the domestic front, the company plans to strengthen its sales and distribution network across West, Central, East and South India as it moves towards a broader Pan-India presence.
Aptus Pharma also plans to explore opportunities in Africa, the Middle East and Latin America through product registrations, export partnerships and other business arrangements. The company said the expansion will be pursued based on commercial viability, market conditions and regulatory approvals.